CLN-049, a novel FLT3/CD3 bispecific T-cell engager, has received fast track designation from the FDA for the treatment of ...

The FDA has granted premarket approval (PMA) to the IsoPSA test, a novel, blood-based in vitro diagnostic kit designed to ...

Tovorafenib provides durable disease control in pediatric patients with relapsed or refractory low-grade glioma harboring ...

Cabozantinib plus nivolumab showed a 71% response rate in FH-dRCC, extending efficacy beyond non-clear cell RCC. The study ...

November 2025 saw pivotal FDA approvals, including durvalumab for gastric cancers and pembrolizumab/enfortumab vedotin for ...

This discussion looks ahead at how the role of PD-1 inhibitors may continue to evolve in the treatment of esophageal squamous ...

This discussion provides a forward-looking discussion on how the role of PD-1 inhibitors may continue to evolve in the ...

Temferon shows consistent survival metrics in glioblastoma patients with unmethylated MGMT, with 44% reaching 18-month ...

This discussion outlines several emerging therapeutic approaches currently under investigation for advanced gastric and ...

During a live event, Thomas G. Martin, MD, discussed the importance of controlling disease and avoiding barriers to access so patients with multiple myeloma can receive CAR T-cell therapy.

The FDA has approved pegfilgrastim-unne (Armlupeg) for the treatment of patients with nonmyeloid cancers undergoing treatment with myelosuppressive anticancer drugs linked to a significant chance of ...

Combined androgen blockade shows significant survival benefits over single-agent ADT in high-risk prostate cancer, as demonstrated by the PRESTO, EMBARK, and ENZARAD trials. The PRESTO trial ...